We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · January 18, 2022

Tucatinib Added to Trastuzumab and Capecitabine for Pretreated HER2+ Metastatic Breast Cancer ± Brain Metastases

Annals of Oncology

 

Additional Info

Annals of Oncology
Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis
Ann. Oncol 2021 Dec 22;[EPub Ahead of Print], G Curigliano, V Mueller, V Borges, E Hamilton, S Hurvitz, S Loi, R Murthy, A Okines, E Paplomata, D Cameron, LA Carey, K Gelmon, GN Hortobagyi, I Krop, S Loibl, M Pegram, D Slamon, J Ramos, W Feng, E Winer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading